All Oncology News

China’s State Administration of Drug Administration has approved ado-trastuzumab emtansine for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease following a neoadjuvant trastuzumab-based regimen.

Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.

Sandy W. Wong, MD, discusses treatments in the pipeline for multiple myeloma.

The United Kingdom’s National Institute for Health and Care Excellence will not recommend osimertinib as a frontline treatment for patients with locally advanced or metastatic EGFR-mutant non–small cell lung cancer.

Narendranath Epperla, MD, MS, reflects on recent advances in Hodgkin lymphoma and non-Hodgkin lymphoma.

Nina Shah, MD, discusses newer treatment options in the frontline and maintenance settings in multiple myeloma. 

Lloyd Damon, MD, discusses the evolution of the treatment paradigm in acute lymphoblastic leukemia.

The European Commission has granted marketing authorization for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

The European Commission has granted a conditional marketing authorization to polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for hematopoietic stem cell transplant.

Surufatinib improved progression-free survival compared with placebo in patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumors for whom there is no effective therapy.

Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.

Francisco J. Esteva, MD, PhD, discusses the cost-saving potential of biosimilars in breast cancer and historical experience with their use.

The FDA has granted an orphan drug designation to durvalumab and tremelimumab for the treatment of patients with hepatocellular carcinoma.

The FDA has granted a priority review designation to a biologics license application for belantamab mafodotin as a treatment for patients with relapsed/refractory multiple myeloma who received prior therapy with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

The anti–PD-1 agent tislelizumab (BGB-A317) in combination with chemotherapy improved progression-free survival compared with chemotherapy alone as a first-line treatment for patients with advanced squamous non–small cell lung cancer.

Bita Fakhri, MD, discusses data from several recent trials in chronic lymphocytic leukemia and focused on other regimens moving through the pipeline.

Weiyun Z. Ai, MD, PhD, discusses some of the most pivotal advances that have been made in the fields of T-cell lymphoma and Hodgkin lymphoma in recent years.

The FDA has granted a priority review designation to a supplemental new drug application for olaparib (Lynparza) for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious or somatic homologous recombination repair gene mutations, and who have also progressed on prior therapy with a new hormonal agent.

Neil Dunavin, MD, MS, highlights criteria to consider when approaching treatment selection for patients with myelofibrosis and discussed next steps for the field.

Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.

Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.

Saad Z. Usmani, MD, FACP, discusses the results of the CANDOR trial and the impact of these data on clinical practice in multiple myeloma.

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

He James Zhu, MD, PhD, discusses the role of elective nodal irradiation in breast cancer and research efforts that may answer some remaining questions with this modality.

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

Howard A. "Skip" Burris, III, MD, FACP, FASCO, discusses the progress that has been made in metastatic triple-negative breast cancer and the work being done to broaden the utility of novel approaches.

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.